Company intelligence / Profile preview

Adaptilens

Boston / Newton Centre / Newton, Massachusetts, United Statesadaptilens.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Adaptilens is developing a first-in-class, soft and flexible accommodating intraocular lens designed to mimic the natural human eye’s ability to focus at multiple distances. The company has raised $17.5 million in Series A funding to advance its A-IOL through first-in-human trials. No clinical results have been reported yet as the company remains pre-clinical.

Therapeutic areas: Ophthalmology
Modalities: DevicePolymer-based medical device (Accommodating intraocular lens)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Adaptilens A-IOL

Pre-clinical

Indications: Cataracts

Partnerships

Perceptive Xontogeny Venture Funds (PXV Funds) – lead investor and strategic partner for development support

Beyond the preview

Go deeper on Adaptilens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adaptilens.

Explore the full profile